12.25
-0.099(-0.81%)
Currency In GBp
Address
Griffin Court
London, EC1A 9PN
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 3763 7499
Website
Sector
Healthcare
Industry
Biotechnology
Employees
81
First IPO Date
April 25, 1996
Name | Title | Pay | Year Born |
Mr. Bram Goorden M.Sc. | Chief Executive Officer & Director | 339,269 | 1973 |
Mr. Grant Robert Nash | Chief Financial Officer, Company Secretary & Executive Director | 221,000 | 1976 |
Prof. Derek Lionel Glendon Hill Ph.D. | Co-Founder and President of Regulatory Science & External Relations | 387,006 | 1966 |
Prof. Daniel Rueckert | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
Dr. Robin Wolz | Chief Scientific Officer | 0 | N/A |
Prof. David Hawkes CPhys, FInstP, FIPEM, FREng, Ph.D. | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
Mr. Lammert Albers | Chief Business Officer | 0 | N/A |
Prof. Joseph Hajnal | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
Dr. John Hall | Senior Vice President of Business Development | 0 | 1979 |
Ms. Hannah Esfahanian | HR Manager | 0 | N/A |
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.